This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Market Withdrawal of Zomepirac as a Case Study

Dennis Ross-Degnan, ScD; Stephen B. Soumerai, ScD; Eric E. Fortess, ScD, MPH; Jerry H. Gurwitz, MD

JAMA. 1993;270(16):1937-1942.

Abstract
Objective.
—To examine changes in the prescribing of analgesics after the market entry and subsequent withdrawal of zomepirac sodium, a nonsteroidal anti-inflammatory drug (NSAID), following repeated reports of zomepirac-related deaths.

Design.
—To evaluate this natural quasi experiment, we conducted time-series analyses to compare prescribing in two cohorts of primary care physicians from July 1980 through September 1983.

Setting.
—Study physicians provided outpatient pharmaceutical care to patients enrolled in the New Jersey Medicaid program.

Participants.
—We identified 260 primary care physicians who provided 10 or more prescriptions for zomepirac (zomepirac prescribers) and 308 who provided 10 or more prescriptions for NSAIDs other than zomepirac (other-NSAID prescribers) in Medicaid during the study period.

Main Outcome Measures.
—Monthly rates of prescribing for zomepirac and several categories of substitute analgesics among Medicaid patients seen by study physicians.

Main Results.
—Zomepirac accounted for a stable 11.0% of analgesic prescribing among the zomepirac-prescriber cohort; label changes and manufacturer product-risk warnings 11 months before the product's withdrawal from the market had no impact on use. After market entry, zomepirac prescribers reduced use of other NSAIDs and propoxyphene (hydrochloride or napsylate) in comparison with other-NSAID prescribers (-8.1% and -2.8% of total analgesic prescribing, respectively; P<.001). After the product's withdrawal from the market, zomepirac prescribers showed significant increases in relative prescribing of other NSAIDs (+6.8%; P<.001), propoxyphene (+2.1%; P<.05), and analgesics containing barbiturates (+2.7%; P<.001).

Conclusions.
—The sudden withdrawal of zomepirac from the market resulted in substitutions not only of other NSAIDs, but also of alternative analgesics that carry risks of habituation and adverse effects. Apparent gains in patient safety resulting from market withdrawal of medications must be evaluated in comparison with risks of medications likely to be substituted.

(JAMA. 1993;270:1937-1942)

Author Affiliations
From the Drug Policy Research Group, Department of Social Medicine, and the Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, Mass (Drs Ross-Degnan and Soumerai); the Department of Public Management/Health Administration Concentration, Suffolk University, Boston, Mass (Dr Fortess); and the Program for Analysis of Clinical Strategies, Gerontology Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (Dr Gurwitz).

Footnotes
Reprint requests to Department of Ambulatory Care and Prevention, Harvard Medical School, 126 Brookline Ave, Suite 200, Boston, MA 02215 (Dr Soumerai).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of New York State Regulatory Action on Benzodiazepine Prescribing and Hip Fracture Rates
Wagner et al.
ANN INTERN MED 2007;146:96-103.
ABSTRACT | FULL TEXT  

Racial disparities in access after regulatory surveillance of benzodiazepines.
Pearson et al.
Arch Intern Med 2006;166:572-579.
ABSTRACT | FULL TEXT  

Failure of Internet-based audit and feedback to improve quality of care delivered by primary care residents
Simon and Soumerai
Int J Qual Health Care 2005;17:427-431.
ABSTRACT | FULL TEXT  

Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women's Health Initiative
Majumdar et al.
JAMA 2004;292:1983-1988.
ABSTRACT | FULL TEXT  

Benzodiazepine Use and Hip Fractures in the Elderly: Who Is at Greatest Risk?
Wagner et al.
Arch Intern Med 2004;164:1567-1572.
ABSTRACT | FULL TEXT  

Length-of-Stay Policies and Ascertainment of Postdischarge Problems in Newborns
Madden et al.
Pediatrics 2004;113:42-49.
ABSTRACT | FULL TEXT  

Effects of state surveillance on new post-hospitalization benzodiazepine use
Wagner et al.
Int J Qual Health Care 2003;15:423-431.
ABSTRACT | FULL TEXT  

Effects on Breastfeeding of Changes in Maternity Length-of-Stay Policy in a Large Health Maintenance Organization
Madden et al.
Pediatrics 2003;111:519-524.
ABSTRACT | FULL TEXT  

Effects of a Law against Early Postpartum Discharge on Newborn Follow-up, Adverse Events, and HMO Expenditures
Madden et al.
NEJM 2002;347:2031-2038.
ABSTRACT | FULL TEXT  

Impact of a Health Maintenance Organization Hospitalist System in Academic Pediatrics
Landrigan et al.
Pediatrics 2002;110:720-728.
ABSTRACT | FULL TEXT  

The Problem of Medical Misadventures: A Review of E. Haavi Morreim's Holding Health Care Accountable
Furrow
J Law Med Ethics 2001;29:381-393.
 

Lessons from international experience in controlling pharmaceutical expenditure. I: influencing patients
Freemantle and Bloor
BMJ 1996;312:1469-1471.
FULL TEXT  

The Impact of Clinical Trials on the Use of Medications for Acute Myocardial Infarction: Results of a Community-Based Study
Col et al.
Arch Intern Med 1996;156:54-60.
ABSTRACT  

Examining Product Risk in Context: The Case of Zomepirac
Spielberg
JAMA 1994;272:1252-1252.
ABSTRACT  

Withdrawal of a Drug From the Market: What Should the Prescriber Do?
Ross-Degnan et al.
JAMA 1994;272:1253-1253.
ABSTRACT  

Examining Product Risk in Context: The Case of Zomepirac
Musa
JAMA 1994;272:1252-1252.
ABSTRACT  

Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia
Soumerai et al.
NEJM 1994;331:650-655.
ABSTRACT | FULL TEXT  

Withdrawl of a Drug From the Market: What Should the Prescriber Do?
Goyan
JAMA 1993;270:1976-1977.
ABSTRACT